ScreenerHero
SIGHTGenSight Biologics S.A.
EPA · FR · Healthcare · Biotechnology · gensight-biologics.com
0.1148EUR+9.13%Mkt Cap: 29.26M $P/E: —

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap29.26M $
Enterprise Value36.55M $
Revenue (TTM)708.70K $
Gross Profit708.70K $
Net Income (TTM)-13.08M $
Revenue/Share0.0043 USD
Last Price0.1148 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013183985
Valuation
P/E (Trailing)—
P/E (Forward)-0.13
PEG—
EV/EBITDA-3.06
EV/Revenue51.57
P/S37.83
P/B-0.93
EPS (TTM)-0.08
EPS (Forward)-0.81
52W Range
0.075224% of range0.2390
52W High0.2390 EUR
52W Low0.0752 EUR
Profitability
Gross Margin100.00%
Oper. Margin-705.96%
EBITDA Margin0.00%
Profit Margin-1203600.00%
ROE48.26%
ROA-145.78%
Growth
Revenue Growth-32.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.97M $
CapEx (TTM)4.35K $
FCF Margin-1110.64%
FCF Yield-26.90%
Net Debt11.36M $
Net Debt/EBITDA-0.95
Balance Sheet
Debt/Equity-0.52
Current Ratio0.39
Quick Ratio0.32
Book Value/Sh-0.1130 EUR
Cash/Share0.0110 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.3050 EUR
Upside (mean)+165.7%
Target Range0.2100 EUR – 0.4000 EUR
€0.2100+165.7% to mean€0.4000
# Analysts2
Ownership
Shares Out.234.47M
Float168.52M
Insiders7.07%
Institutions41.19%
Technical
SMA 500.0845 (+35.8%)
SMA 2000.0891 (+28.8%)
Beta0.64
S&P 52W Chg18.16%
Avg Vol (30d)1.14M
Avg Vol (10d)2.36M
Technical Indicators
RSI (14)70.1
MACD0.0057
MACD Signal0.0033
MACD Hist.+0.0024
BB Upper0.1086 EUR
BB Middle0.0895 EUR
BB Lower0.0704 EUR
BB Width42.66%
ATR (14)0.0059 EUR
Vol Ratio (20d)0.69x